VIS171

Phase 1Small molecule

Otsuka

VIS171 is one of 6 small molecule programs targeting Systemic Lupus Erythematosus (SLE). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus Erythematosus (SLE)Active, not recruiting

Systemic Lupus Erythematosus (SLE)Phase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Systemic Lupus Erythematosus (SLE)

#DrugCompanyPhaseTrials

BMS-986165

Bristol-Myers Squibb

Phase 3

1 2

SG301

HHangzhou Sumgen Biotech Co., Ltd.

Phase 2

2 3

ESG206

SShanghai Escugen Biotechnology Co., Ltd

Phase 2

1 4

Cizutamig

CCandid Therapeutics

Phase 1

1 5

SAR448501

Sanofi

Phase 1

1 6

VIS171

Otsuka

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Systemic Lupus Erythematosus (SLE)

NCT06799520

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and with Autoimmune Disease)

Completed·VVisterra, Inc.·Phase 1·NCT05418101·61 enrolled

Systemic Lupus Erythematosus (SLE)1 trial

A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Subcutaneous VIS171 in Participants With Autoimmune Disease(s)

Active, not recruiting· Otsuka logo

Otsuka·Phase 1·NCT06799520·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VIS171. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VIS171 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VIS171. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Otsuka

VIS171

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Autoimmune Disease1 trial

Systemic Lupus Erythematosus (SLE)1 trial

References

Drug Info

Quick Facts

Related News